Drug intelligence / Profile preview

CD16-enhanced HSC-engineered NKT cells

Development stage: Preclinical
Lead developer: University of California, Los Angeles
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CD16-enhanced HSC-engineered NKT cells are an allogeneic, off-the-shelf cellular immunotherapy developed using a hematopoietic stem cell (HSC) engineering platform. These cells are genetically modified to express an invariant natural killer T (NKT) cell receptor (TCR) and a high-affinity, non-cleavable CD16a (FcγRIIIa) receptor. This dual-targeting approach allows the cells to recognize tumors via CD1d-presented glycolipid antigens and to mediate potent antibody-dependent cellular cytotoxicity (ADCC) when used in combination with tumor-specific monoclonal antibodies. Additionally, these cells are designed to deplete immunosuppressive tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment. The platform utilizes a scalable, feeder-free in vitro differentiation system to produce high-purity NKT cells with superior metabolic fitness and persistence compared to peripheral blood-derived counterparts.

Other names: CD16-enhanced hematopoietic stem cell-engineered invariant natural killer T cellsCD-16-enhanced hematopoietic stem cell-engineered invariant natural killer T cellsCD 16-enhanced hematopoietic stem cell-engineered invariant natural killer T cells

Targets

iNKT TCR (Invariant natural killer T-cell receptor)MICB (Major histocompatibility complex class i-related protein B)IgG Fc (Immunoglobulin G Fc region)

Beyond the preview

Go deeper on CD16-enhanced HSC-engineered NKT cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD16-enhanced HSC-engineered NKT cells.

Explore the full profile